Finanzen von Pediatrix Medical Group Inc (MD)MDPediatrix Medical Group Inc

Evaluating the bottom line, Pediatrix Medical Group Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 13.41%, while the net margin is 8.17%. These profitability ratios, combined with a Return on Equity (ROE) of 20.39%, provide a clear picture of how effectively MD converts its operational activities into shareholder value.

In the context of the broader market, MD competes directly with industry leaders such as ADUS and NEO. With a market capitalization of $2.18B, it holds a significant position in the sector. When comparing efficiency, MD's gross margin of 100.00% stands against ADUS's 31.12% and NEO's 45.56%. Such benchmarking helps identify whether Pediatrix Medical Group Inc is trading at a premium or discount relative to its financial performance.

Pediatrix reported Q2 revenues of $487.8 million, a 4% year-over-year increase, and an adjusted EBITDA of $76 million, reflecting solid financial performance despite challenges.